Abstract：
BACKGROUND: COVID-19 booster dose vaccination acceptance and actual vaccination behavior is not known among Egyptian individuals with autoimmune and rheumatic diseases (ARDs). The aim of this study was to investigate the acceptability of booster dose of the COVID-19 vaccine, as well as the factors that drive and inhibit that acceptance among Egyptian patients diagnosed with ARDs.
METHODS: This interview-based, cross-sectional analytical study was carried out on ARD patients from 20 July to 20 November 2022. A questionnaire was created to assess sociodemographic and clinical data, as well as COVID-19 vaccination status and the intention to receive a COVID-19 vaccine booster dose, perception of health benefits of it in addition to the perceived barriers and/or concerns.
RESULTS: A total of 248 ARD patients were included, with a mean age of 39.8 years (SD = 13.2), and 92.3% were females. Among them, 53.6% were resistant to the COVID-19 booster dose, whereas 31.9% were acceptant and 14.5% were hesitant. Those who were administering corticosteroids and hydroxychloroquine shown significantly greater booster hesitancy and resistance (p = 0.010 and 0.004, respectively). The primary motivation for taking a booster dose among the acceptant group was own volition (92%). Most acceptants believed that booster dose can prevent serious infection (98.7%) and community spread (96.2%). Among the hesitant and resistant groups, the main concerns for booster dose were fear about its major adverse effects (57.4%) and long-term impact (45.6%).
CONCLUSIONS: There is a low acceptability rate of booster dose of COVID-19 vaccine among Egyptian patients with ARD diseases. Public health workers and policymakers need to make sure that all ARD patients get clear messages about accepting the COVID-19 booster dose.
METHODS: This interview-based, cross-sectional analytical study was carried out on ARD patients from 20 July to 20 November 2022. A questionnaire was created to assess sociodemographic and clinical data, as well as COVID-19 vaccination status and the intention to receive a COVID-19 vaccine booster dose, perception of health benefits of it in addition to the perceived barriers and/or concerns.
RESULTS: A total of 248 ARD patients were included, with a mean age of 39.8 years (SD = 13.2), and 92.3% were females. Among them, 53.6% were resistant to the COVID-19 booster dose, whereas 31.9% were acceptant and 14.5% were hesitant. Those who were administering corticosteroids and hydroxychloroquine shown significantly greater booster hesitancy and resistance (p = 0.010 and 0.004, respectively). The primary motivation for taking a booster dose among the acceptant group was own volition (92%). Most acceptants believed that booster dose can prevent serious infection (98.7%) and community spread (96.2%). Among the hesitant and resistant groups, the main concerns for booster dose were fear about its major adverse effects (57.4%) and long-term impact (45.6%).
CONCLUSIONS: There is a low acceptability rate of booster dose of COVID-19 vaccine among Egyptian patients with ARD diseases. Public health workers and policymakers need to make sure that all ARD patients get clear messages about accepting the COVID-19 booster dose.
摘要：
背景：在患有自身免疫和风湿性疾病（ARD）的埃及个体中，尚不知道COVID-19加强剂量疫苗接种的接受和实际疫苗接种行为。这项研究的目的是调查COVID-19疫苗加强剂量的可接受性，以及驱动和抑制被诊断为ARD的埃及患者接受这种接受的因素。
方法：此访谈基于，对2022年7月20日至11月20日的ARD患者进行了横断面分析研究.创建了一份问卷来评估社会人口统计学和临床数据，以及COVID-19的疫苗接种状况和接受COVID-19疫苗加强剂量的意图，除了感知的障碍和/或担忧之外，对它的健康益处的感知。
结果：共纳入248例ARD患者，平均年龄39.8岁（SD=13.2），女性占92.3%。其中,53.6%对COVID-19加强剂量耐药，而31.9%是接受者，14.5%是犹豫者。那些服用皮质类固醇和羟氯喹的人表现出明显更大的加强犹豫和抵抗（分别为p=0.010和0.004）。在接受组中，服用加强剂量的主要动机是自己的意志（92％）。大多数接受者认为加强剂量可以防止严重感染(98.7%)和社区传播(96.2%)。在犹豫和抵抗的群体中，加强剂量的主要担忧是担心其主要不良反应(57.4%)和长期影响(45.6%).
结论：在埃及ARD患者中，COVID-19疫苗加强剂量的接受度较低。公共卫生工作者和政策制定者需要确保所有ARD患者都得到关于接受COVID-19加强剂量的明确信息。
方法：此访谈基于，对2022年7月20日至11月20日的ARD患者进行了横断面分析研究.创建了一份问卷来评估社会人口统计学和临床数据，以及COVID-19的疫苗接种状况和接受COVID-19疫苗加强剂量的意图，除了感知的障碍和/或担忧之外，对它的健康益处的感知。
结果：共纳入248例ARD患者，平均年龄39.8岁（SD=13.2），女性占92.3%。其中,53.6%对COVID-19加强剂量耐药，而31.9%是接受者，14.5%是犹豫者。那些服用皮质类固醇和羟氯喹的人表现出明显更大的加强犹豫和抵抗（分别为p=0.010和0.004）。在接受组中，服用加强剂量的主要动机是自己的意志（92％）。大多数接受者认为加强剂量可以防止严重感染(98.7%)和社区传播(96.2%)。在犹豫和抵抗的群体中，加强剂量的主要担忧是担心其主要不良反应(57.4%)和长期影响(45.6%).
结论：在埃及ARD患者中，COVID-19疫苗加强剂量的接受度较低。公共卫生工作者和政策制定者需要确保所有ARD患者都得到关于接受COVID-19加强剂量的明确信息。
